NV 5138
Alternative Names: NV-5138; SPN 820; SPN-820/821; SPN-821Latest Information Update: 08 Mar 2024
At a glance
- Originator Navitor Pharmaceuticals; X-Chem
- Developer Navitor Pharmaceuticals; Supernus Pharmaceuticals
- Class Antidepressants; Pentanoic acids; Small molecules
- Mechanism of Action MTORC1 protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Depressive disorders; Major depressive disorder
Most Recent Events
- 15 Feb 2024 Phase-II clinical trials in Major depressive disorder (Adjunctive treatment) in USA (PO) (NCT06235905)
- 08 Nov 2023 Supernus Pharmaceuticals plans a phase II trial for Major depressive disorders before end of 2023
- 28 Feb 2022 Phase-II clinical trials in Depressive disorders (Treatment-resistant) in USA (PO) (NCT05066672)